US drug major Bristol-Myers Squibb has turned to Celltrion, a
company based in South Korea, for the manufacture of biologic
drugs, in another example of companies 'offshoring' production to
Asia, reports Phil Taylor.
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Switzerland's Siegfried Group, a specialist in active
pharmaceutical ingredients (APIs), dosage forms and
biopharmaceuticals, has boosted its position in the production of
controlled substances with the acquisition of US-based...
Italy's fine chemicals industry organisation, Afaquim, is
organising a conference in September aimed at coordinating the
efforts of European active pharmaceutical ingredient (API)
suppliers in the face of increasing competition...
Lonza is planning a major exansion of its peptides manufacturing
capacities at Visp, Switzerland, in response to what it said was
'the increased demand for peptide active pharmaceutical ingredients
The fine chemicals business unit of Lanxess, which was spun-out
from Germany's Bayer earlier this year and provides custom
manufacturing services to the pharmaceutical and other industries,
has said it plans to expand its geographic...